CoQ10 treatment of patients with CHF and effects of BNP levelстатьяТезисы
Статья опубликована в высокорейтинговом журнале
Информация о цитировании статьи получена из
Web of Science
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 28 октября 2016 г.
Аннотация:Background: CoQ10 is a powerful antioxidant and is one of recommended for CHF
treatment. Decreased level of myocardial CoQ10 is correlated with the severity of
symptoms and the degree of left ventricular dysfunction. Brain natriuretic peptide
(BNP) is a peptide, which has recently been used in the differential diagnosis and
follow-up of patients with heart failure. It is well known that the severity of the disease
also correlates with the plasma BNP levels.
Purpose: To evaluate the effects of long-term coenzyme Q10 treatment as part of
standard therapy in patients with NYHA class II-III chronic heart failure on plasma
BNP levels, left ventricular ejection fraction, and the 6-minute walk test.
Materials and Methods: 78 patients with NYHA class II-III chronic heart failure aged
from 40 to 70 years with EF less than 45% were randomized in clinical trial. During
the study period (24 weeks) participants received solubilized oral form of CoQ10 (90
mg/d) or placebo in addition to standard medical therapy. Left ventricular ejection
fraction, 6-minute walk test, plasma brain natriuretic peptide (BNP) (fluorescent
analyser with test strips) and CoQ10 levels (HPLC with electrochemical detection)
were measured in all patients prior to and after six months treatment.
Results: In 37 patients from 78 the baseline level of BNP was below 100 pg/ml. 6
months administration of CoQ10 did nor change BNP level, but in placebo group
BNP level increased by 176% ((=0,0092). In group of 41 patients baseline level of
BNP was above 100 pg/ml level. In this group administration of CoQ10 was followed
by the decrease in BNP level by 6.8% (p=0.02) whereas in placebo group BNP level
did not change.
Conclusion: 6 months administration of coenzyme Q10 prevents progression of
congestive heart failure in patients with reduced contractility and baseline plasma
BNP levels within normal ranges (less than 100 pg/ml) and leads to a significant reduction of BNP levels in patients with initial BNP levels higher than 100 pg/ml,
increase in left ventricular ejection fraction and improvement in exercise tolerance.